Login to Your Account

Ipsen, Syntaxin Partner to Develop Botulinum Toxin Drugs

By Nuala Moran

Friday, October 21, 2011
LONDON – Ipsen SA has followed up an equity investment in Syntaxin Ltd with a research collaboration that will net the UK botulinum toxin specialist $9 million over three years for discovery work, with additional fees for any compounds that go into development, and a potential further $90 million in commercial milestones.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription